89bio, Inc. (ETNB)
Total Valuation
89bio has a market cap or net worth of $1.06 billion. The enterprise value is $506.66 million.
Market Cap | 1.06B |
Enterprise Value | 506.66M |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, after market close.
Earnings Date | May 2, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
89bio has 93.50 million shares outstanding. The number of shares has increased by 104.48% in one year.
Shares Outstanding | 93.50M |
Shares Change (YoY) | +104.48% |
Shares Change (QoQ) | +5.85% |
Owned by Insiders (%) | 0.89% |
Owned by Institutions (%) | 106.41% |
Float | 69.47M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.97 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.04, with a Debt / Equity ratio of 0.05.
Current Ratio | 20.04 |
Quick Ratio | n/a |
Debt / Equity | 0.05 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -27.85 |
Financial Efficiency
Return on equity (ROE) is -31.00% and return on invested capital (ROIC) is -26.84%.
Return on Equity (ROE) | -31.00% |
Return on Assets (ROA) | -27.80% |
Return on Capital (ROIC) | -26.84% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.03M |
Employee Count | 70 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, 89bio has paid $3.87 million in taxes.
Income Tax | 3.87M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.83% in the last 52 weeks. The beta is 0.95, so 89bio's price volatility has been similar to the market average.
Beta (1Y) | 0.95 |
52-Week Price Change | -30.83% |
50-Day Moving Average | 11.00 |
200-Day Moving Average | 12.88 |
Relative Strength Index (RSI) | 46.71 |
Average Volume (30 Days) | 1,368,095 |
Short Selling Information
The latest short interest is 11.11 million, so 11.88% of the outstanding shares have been sold short.
Short Interest | 11.11M |
Short Previous Month | 10.86M |
Short % of Shares Out | 11.88% |
Short % of Float | 15.99% |
Short Ratio (days to cover) | 7.98 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -151.20M |
Pretax Income | -138.32M |
Net Income | -142.19M |
EBITDA | -133.26M |
EBIT | -133.53M |
Earnings Per Share (EPS) | -$2.00 |
Balance Sheet
The company has $578.87 million in cash and $27.11 million in debt, giving a net cash position of $551.76 million or $5.90 per share.
Cash & Cash Equivalents | 578.87M |
Total Debt | 27.11M |
Net Cash | 551.76M |
Net Cash Per Share | $5.90 |
Equity / Book Value | 536.31M |
Book Value Per Share | 5.74 |
Working Capital | 563.92M |
Cash Flow
In the last 12 months, operating cash flow was -$129.19 million and capital expenditures -$4,000, giving a free cash flow of -$129.19 million.
Operating Cash Flow | -129.19M |
Capital Expenditures | -4,000 |
Free Cash Flow | -129.19M |
FCF Per Share | -$1.82 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
89bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -104.48% |
Shareholder Yield | -104.48% |
Earnings Yield | -13.43% |
FCF Yield | -12.21% |
Analyst Forecast
The average price target for 89bio is $28.83, which is 154.91% higher than the current price. The consensus rating is "Buy".
Price Target | $28.83 |
Price Target Difference | 154.91% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -12.77% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |